和黄医药(00013)：达唯珂®(TAZVERIK®)获纳入首版国家商业健康保险创新药品目录

Group 1 - The core announcement is that Hutchison China MediTech Limited (和黄医药) has successfully negotiated with the National Healthcare Security Administration of China to include its drugs, Elunate (爱优特), Orpathys (沃瑞沙), and Sulanda (苏泰达), in the new version of the National Medical Insurance Drug List effective from January 1, 2026 [1] - Tazverik (达唯珂) has been included in the inaugural National Commercial Health Insurance Innovative Drug List, indicating a significant step for the company's product portfolio in the commercial insurance sector [1]